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Recent developments in our ability to predict breast cancer risk necessitates primary care physicians learn to
evaluate breast cancer risk and its importance in shaping decisions concerning surveillance and risk reduction
measures. This article reviews the current opinion on risk assessment and management of women with an
increased risk of breast/ovarian cancer. Management options are given for women at slightly, moderately and
highly elevated breast cancer risk, as well as for BRCA1/2 carriers, based on currently available evidence.
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Introduction
Approximately 15–20% of all breast cancers occur within the
context of familial breast cancer. Recent advances in molecular
genetics allow us to identify individuals at risk, and new develop-
ments in the clinical management of familial breast/ovarian
cancer have brought this new field to the attention of a wide range
of health care professionals.
Population-based breast cancer screening with mammography
among women from 50 to 70 years of age has been performed for
many years and has been shown to reduce breast cancer mortality
by up to 35%. However, for women at increased breast cancer
risk no randomized trials have been conducted and the best
surveillance strategy remains unknown. In addition, a number of
interventions have been developed in recent years to reduce the
risk of breast and ovarian cancer. There is emerging evidence that
chemoprevention with selective estrogen receptor modulators
may reduce the incidence of breast cancer in healthy women at
increased risk for breast cancer. But the most effective class of
endocrine agent, the optimal duration or the age at which chemo-
prevention should begin have not yet been defined. Recent
studies have shown substantial benefit of surgical interventions,
such as prophylactic mastectomy and/or oophorectomy, for a
select group of moderate to high-risk women. Since surgical
interventions are irreversible and have far-reaching repercus-
sions, a thorough overview with respect to their advantages and
limitations is needed in order to take an appropriate decision.
In recent years, many professional groups, including the Swiss
Institutes for Applied Cancer Research Network for Cancer
Predisposition Testing and Counseling [1], have developed
specialized multidisciplinary programs for familial cancer. In
order to provide optimal care, breast cancer risk needs to be
assessed as precisely as possible and appropriate decisions con-
cerning surveillance and risk reduction measures have to be taken
based on evidence. This review aims to summarize the currently
available evidence concerning surveillance and risk reduction
measures for women at increased breast/ovarian cancer risk.
Risk assessment
Breast cancer risk needs to be assessed as precisely as possible to
enable appropriate decisions to be taken concerning surveillance
and risk reduction measures. Claus  and Gail  are two models for
predicting breast cancer risk which are widely used in research
studies and clinical counseling [2, 3]. Both have their limitations
and the risk estimated from these two models may differ for an
individual patient. However, these models provide the best
methods currently available for individual risk assessment.
Neither the Gail nor the Claus model were designed to estimate
the probability of a patient carrying a BRCA mutation, but other
models have been designed for that purpose.
Risk assessment models
The Claus model. The Claus model [2] projects the probability
of developing breast cancer for women with a family history of
breast cancer using empirical data from the Cancer and Steroid
Hormone (CASH) study. This model is based on assumptions of
the prevalence of high-penetrance genes for susceptibility to
breast cancer. The risk estimate is based on the following:
• a woman’s current age;
• the number of first- and second-degree relatives with breast
cancer;
• the age of cancer onset in first- and second-degree relatives.
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This model provides cumulative risk estimates for several dif-
ferent family history configurations but does not take other risk
factors associated with lifestyle and environmental factors into
account.
The maximum number of affected family members this model
can accommodate is two. Therefore it may underestimate the
breast cancer risk for women with three or more affected family
members. Pedigree data are not taken into account and important
genetic information conveyed by the presence of unaffected
family members is minimized.
The Gail model. The Gail model [3] projects the probability of
developing both invasive and noninvasive breast cancer based on
some of the known risk factors for breast cancer. The Gail model
predicts the cumulative risk of breast cancer by decade up to
90 years of age. It is based on the major predictors of risk identi-
fied in the Breast Cancer Detection Demonstration Project, a
large mammographic screening project in the 1970s. Utilized risk
factors are as follows:
• current age;
• age at menarche;
• age at first live birth;
• number of previous breast biopsies;
• presence of atypical hyperplasia;
• number of first-degree relatives with breast cancer.
To calculate breast cancer risk with the Gail model, a woman’s
risk factors are translated into an overall risk score by multiplying
her relative risks from several categories. The risk score is then
multiplied by an adjusted population risk of breast cancer to
determine the individual risk of breast cancer. The Gail model
does not consider second-degree relatives, paternal relatives, age
of onset of breast cancer in the affected relative or cases of
ovarian cancer in the family and thus may overestimate the risk in
women whose first-degree relatives had breast cancer at an old
age and underestimate the risk in women whose first-degree
relatives had breast cancer at a young age.
Because the Gail model includes only first-degree relatives in
its risk calculation and does not consider second-degree relatives,
paternal relatives, age of onset of breast cancer in the affected
relative or cases of ovarian cancer, it is not an appropriate model
for women with a family history of multiple relatives with breast
cancer which is suggestive of an inherited breast cancer predis-
position. The Gail model has been validated in four populations
[4–7] as a predictor of breast cancer risk in women who adhere to
regular mammography screening. Some of these studies indicate
that the model overestimates risk in women who do not undergo
mammographic screening regularly.
Models for predicting likelihood of BRCA1 or BRCA2 mutations.
Several studies have assessed the frequency of BRCA1 or BRCA2
mutations in women with breast or ovarian cancer. There have
been population-based studies as well as studies from clinical
referral centers.
Personal characteristics associated with an increased likeli-
hood of BRCA1 or BRCA2 mutations are as follows:
• breast cancer diagnosed <40 years of age;
• bilateral breast cancer, especially at a young age;
• a history of both breast and ovarian cancer.
Family history characteristics associated with an increased likeli-
hood of BRCA1 or BRCA2 mutations [8] are as follows:
• two or more family members <50 years of age with breast
cancer;
• both breast and ovarian cancer in the family;
• male breast cancer;
• one or more family members <50 years of age with breast
cancer and with Ashkenazi Jewish background;
• ovarian cancer and Ashkenazi Jewish background.
In one multicenter study [9], the likelihood of finding a BRCA1 or
BRCA2 mutation was >50% if a breast cancer-affected individual
was <50 years of age and had at least one first- or second-degree
relative with breast or ovarian cancer or if a patient had bilateral
breast cancer, both breast and ovarian cancer or a diagnosis of
breast cancer <40 years of age and relatives with both breast and
ovarian cancer.
In a German referral clinic, families were evaluated for BRCA1
mutation if three or more family members developed breast or
ovarian cancer with at least two of the affected family members
being <60 years of age. A mutation was found in 33% of families
with both breast and ovarian cancers and 17% of the families
with breast cancer only. A referral clinic in Pennsylvania found
BRCA1 mutations in 40% of families with breast and/or ovarian
cancer but only in 7% of families with breast cancer only.
These studies indicate that among women with personal or
family history characteristics suggesting an increased risk of breast
cancer, a BRCA1 or BRCA2 mutation is more likely to be found if
the family history includes the following:
• members with both breast and ovarian cancer;
• two or more primary breast or ovarian cancers;
• multiple breast cancers occurring at an early age.
Statistical models based on these data have been developed to
estimate an individual’s probability using personal and family
history characteristics. Computer programs have been developed
from these models to estimate probabilities based on data entered
by a health professional. One of these, BRCAPRO, is now
available via the Internet (http:// astor.som.jhmi.edu/brcapro). One
of the major differences between this model and those cited
above is its ability to consider the structure of the family pedigree
including both affected and unaffected family members, in
estimating the probability of a BRCA1 or BRCA2 mutation. BRC-
APRO also includes data regarding age at onset of ovarian and
breast cancer, presence of bilateral and male breast cancer and
Ashkenazi Jewish heritage in the probability computation. All
models are based on prevalence, penetrance and mutation
frequency data derived from persons who participated in research
studies of BRCA1 and BRCA2 or who chose to be clinically
tested. Most of the persons tested were affected with cancer. Like
the models cited above, these data are thus likely to be subject
to selection biases with the estimated probabilities depending
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significantly on the BRCA1 and BRCA2 penetrance estimates
chosen. The BRCAPRO model has recently been validated as an
accurate counseling tool for determining the probability of carry-
ing mutations of BRCA1 or BRCA2 [10].
Other breast cancer susceptibility genes that have to be taken
into account when assessing inherited breast cancer. Although
mutations in several genes confer an increased breast cancer risk,
BRCA1, BRCA2 and TP53 appear to be the most relevant in
clinical practice. Estimates of the proportion of inherited breast
cancers due to BRCA1 and BRCA2 mutations range from 30% in
clinical-based families to 84% in the Breast Cancer Linkage Con-
sortium [11–13]. TP53 and PTEN each account for <1% of cases
[14, 15]. Heterozygous ATM mutation carriers have an increased
risk of breast cancer but the magnitude of risk is not quantified
[16]. Other genetic conditions with associated breast cancer risk
include Muir Torre syndrome with MLH1 mutations and Peutz
Jeghers syndrome with LKB1/STKII mutations.
Surveillance
Breast self-examination
The increased risk of early onset breast cancer and reports of the
failure of mammography to detect breast cancer in carriers of
BRCA1 mutations may make breast awareness of greater value in
high-risk women than in average-risk women.
Clinical breast examination
Clinical breast examination detects palpable breast cancers. It
can detect cancers that are not detectable by mammography or
interval cancers between regular mammographic screenings. The
National Breast and Cervical Screening Program recently reported
the results of 753081 clinical breast examinations provided
during the period from 1995 to 1998 to low-income women. A
breast cancer detection rate of 5.1% was observed for an abnor-
mal clinical breast examination with a normal mammogram [17].
The Canadian National Breast Screening Study, a randomized
study to evaluate the effect of mammography over clinical breast
examination, reported after 13 years of follow-up similar death
rates in the combined mammography and clinical breast exam-
ination arm compared with the clinical breast examination only
arm [18]. In the Breast Cancer Detection Demonstration Project,
6.2% of tumors were detected by clinical examination alone
(National Cancer Institute and American Cancer Society, 1979).
Clinical examination may be an important adjunct in screening
for breast cancer in young, high-risk women for whom there is
some doubt about the sensitivity of mammography.
Mammographic screening
A limited number of studies describing the experiences and
results of surveillance in women with familial breast cancer have
been published [19–23]. A recent study suggested that tumors in
BRCA carriers have the same radiological appearance as in
non-carriers [24], which suggests that yearly screening may be
effective. However, a study by Brekelmans et al. [25] observed a
substantial risk of interval cancers in BRCA mutation carriers
undergoing annual mammographic screening, which suggests that
current recommendations of yearly mammographies beginning
between 25 and 35 years of age may be insufficient in this very
high-risk group. This may be due to highly proliferative cancers,
because 70% of BRCA1-associated breast cancers are grade 3
lesions [26]. Moreover, in the group of proven BRCA carriers and
women under the age of 40, 56% and 62% of mammographically
detected breast cancers, respectively, were node positive,
compared with an expected rate of around 31% in this age group
[27, 28]. Although several studies have shown that 60–90% of
breast cancers diagnosed in young women are evident mammo-
graphically [29], breast density is known to be higher in young
women and thus may hamper effective mammographic screening
[30, 31].
Ovarian cancer surveillance
Screening strategies using ultrasound and measurements of
serum CA125 levels may detect ovarian cancer before the onset
of clinical symptoms. However, screening for ovarian cancer has
not been shown to reduce mortality in unselected patients nor is it
clear what the optimal frequency of screening is (NIH Consensus
Development Panel on Ovarian Cancer 1995 [32]).
Transvaginal ultrasound enables the assessment of ovarian size
and morphology. Ovarian enlargement and solid and cystic
morphology may give rise to an index of suspicion for neoplasia.
Ovarian tumors are characterized by a lower than average imped-
ance to blood flow, which may be detected by color flow Doppler.
The sensitivity and specificity of this technique has been reported
to be 98.4% and 99.8%, respectively [33]. The addition of trans-
vaginal ultrasound to CA125 measurements increases specificity
to 100% and gives a positive predictive value of 27% [34, 35].
However, normal physiological changes in the premenopausal
ovary near the time of ovulation have low impedance flow
characteristics similar to those seen in malignancy [36]. There-
fore transvaginal ultrasound should be timed to avoid ovulation
in order to reduce the frequency of false-positive results.
Data are limited with regard to the benefit of pelvic ultrasound
in screening women with an inherited risk of ovarian cancer. One
study examined 1601 women with a family history of ovarian
cancer with pelvic ultrasound; of these scans 3.8% were found to
be abnormal. Only three of 61 women with abnormal scans had
ovarian cancer, two with stage I and one with stage III ovarian
cancer [37]. The NIH Consensus Statement on Ovarian Cancer
recommended that women with a BRCA mutation-associated risk
of ovarian cancer undergo transvaginal ultrasound and serum
CA125 measurement every 6–12 months commencing at 35 years
of age [32]. The Cancer Genetics Studies Consortium task force
has recommended that female carriers of a BRCA1 high-risk
mutation undergo 6–12 monthly screening using transvaginal
ultrasound and serum CA125 measurement beginning at 25–35
years of age [38].
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Risk reduction measures
Chemoprevention
Tamoxifen, a selective estrogen receptor modulator, was the first
drug shown to reduce the incidence of breast cancer in healthy
women. The breast cancer prevention trial randomly assigned
more than 13000 women with a 5-year risk of breast cancer of at
least 1.7% in the Gail model to 5 years of tamoxifen 20 mg or
placebo [39]. After a median follow-up of 4 years, tamoxifen had
reduced the incidence of estrogen receptor-positive (ER+) breast
cancers by 49% compared with placebo. In contrast, two Euro-
pean trials did not find tamoxifen protective [40, 41]. The differ-
ence in results may be related to differences in the design of the
studies and the populations included [42]. A subgroup analysis of
the P-1 trial showed that tamoxifen reduces the breast cancer
incidence among healthy BRCA2 carriers by 62% similar to the
reduction in incidence of ER+ breast cancer among all women in
the breast cancer prevention trial, but tamoxifen use beginning at
≥35 years of age did not reduce breast cancer risk among healthy
BRCA1 carriers [43].
A recently published retrospective study among select women
with BRCA mutations who received adjuvant therapy with
tamoxifen has documented a reduction in risk of contralateral
breast cancer among BRCA carriers [44]. This study examined
the effect of tamoxifen in two groups of patients with either a
BRCA1 or a BRCA2 mutation; namely, in 209 and 374 women
with bilateral and unilateral breast cancer, respectively. Tamoxi-
fen protected against contralateral breast cancer and the risk
reduction was 75% for women who used tamoxifen for 2–4 years.
Moreover, the protective effect of tamoxifen appeared to be
independent from oophorectomy. However, a recent paper by
Li et al. [45] argues that the incidence of contralateral ER– breast
tumors may even be increased with adjuvant tamoxifen therapy.
This may be an important finding with respect to chemo-
prevention in BRCA1 carriers as up to 80% of BRCA1-related
tumors are ER– [46].
Tamoxifen has side-effects such as venous thromboembolism,
endometrial cancer and cataracts. Although tamoxifen maintains
bone density in postmenopausal women [47], it may result in
bone loss in premenopausal women. Raloxifene, a selective
estrogen-receptor modulator, has been approved in the USA for
the prevention and treatment of osteoporosis in postmenopausal
women. The effect of raloxifene on the risk of breast cancer has
been monitored in several ongoing placebo-controlled trials
directed at osteoporosis and other endpoints. The multiple
outcomes of the raloxifene (MORE) trial randomly assigned
7705 women with osteoporosis to raloxifene 120 mg daily or
placebo [48]. After 40 months of follow-up, raloxifene was found
to have reduced the annual odds of breast cancer by 65% and
reduced the risk of invasive breast cancer. At the present time, the
trial of tamoxifen and raloxifene (STAR) evaluates whether
raloxifene is effective in reducing the risk of breast cancer in
postmenopausal women and will provide comparative informa-
tion on the side-effects of these two drugs. However, the most
effective class of endocrine agent, the optimal duration or the age
at which to begin chemoprevention have not yet been defined for
women at increased breast cancer risk. Therefore, chemo-
prevention should only be performed within the context of well
designed clinical trials.
Prophylactic mastectomy
Carriers of BRCA mutations have an increased risk of both breast
and ovarian cancer. For BRCA mutation carriers, the risk of con-
tralateral cancer after breast cancer may exceed 5% per year, and
in non-carriers at or below the age of 50 years with at least one
similarly affected first-degree relative or relative with ovarian
cancer, the rate is estimated to be 2.8% per year [49].
Efficacy. Until very recently there were no prospective trials of
prophylactic mastectomy or oophorectomy for the reduction of
breast or ovarian cancer mortality. Therefore, two groups have
developed theoretical models to facilitate clinical decision
making in these women. Schrag et al. [49] and Grann et al. [50]
modeled the effect of prophylactic mastectomy and oophor-
ectomy on the life expectancy of BRCA carriers to facilitate
clinical decision making. Statistical models estimate that a
30-year-old woman who carries a BRCA mutation may gain 3–5
years of life expectancy from prophylactic mastectomy and
0.5–1.5 years of life expectancy from prophylactic oophor-
ectomy depending on her cumulative risk of cancer. Estimates of
the mean or median age of onset for breast cancer range from 38
to 43 years of age in BRCA1 [51, 52] mutation carriers and from
41 to 45 years of age in BRCA2 mutation carriers [9]. Therefore,
gains of life expectancy decline with age at the time of prophy-
lactic surgery and are minimal for 60-year-old women. This
suggests that the greatest benefit of prophylactic mastectomy
may be expected in a young carrier.
Meijers-Heijboer et al. [53] conducted the first prospective
study of 139 women with BRCA1 and BRCA2 mutations.
Seventy-six women chose to undergo prophylactic bilateral
mastectomy to reduce their breast cancer risk and 63 women
were followed according to a surveillance protocol consisting of
a monthly breast self-examination, a semi-annual breast exam-
ination by a health care professional and annual mammography.
From 1995 annual magnetic resonance imaging (MRI) was
offered. No breast cancers were observed in the 76 women who
underwent bilateral prophylactic mastectomy, whereas eight
breast cancers were detected in the surveillance group. The
observed cancer incidence was consistent with the number
expected from estimates of the penetrance of BRCA1 and BRCA2
mutations. This study supports the retrospective report by Hart-
mann et al. [54], that prophylactic bilateral mastectomy has an
efficacy of 90% in women classified as having a high breast
cancer risk based on family history.
Two large retrospective case series on the use of prophylactic
mastectomy for familial breast cancer risk have been reported in
the literature [54, 55]. The best available evidence concerning
efficacy comes from a cohort analysis of 639 women with a
family history of breast cancer who had bilateral subcutaneous
mastectomy (90%) or total mastectomy (10%) at the Mayo Clinic
from 1960 to 1993 [54]. Approximately two-thirds of the women
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were classified as high risk on the basis that they possessed some
of the features of autosomal dominant breast–ovarian cancer
syndrome. One-third were defined as moderate risk including all
women with a family history of breast cancer that did not meet
the more stringent high-risk criteria. Even with the most con-
servative estimate of breast cancer incidence, prophylactic mast-
ectomy resulted in a 90% reduction of breast cancer incidence.
Similar estimates were derived for the moderate risk group. In a
recent update of the Mayo Clinic study, 26 of 214 high-risk
women have been identified as BRCA1 or BRCA2 mutation
carriers and none of them has developed breast cancer after a
median of 13.4 years of follow-up [56].
However, breast cancer may occur after prophylactic simple
mastectomy [57], which is usually of the subcutaneous form.
Breast tissue may be present in the axilla and abdominal wall
[58]. Historically the surgical options for women who elected to
undergo prophylactic mastectomy have included subcutaneous
mastectomy (usually includes an inframammary incision with
removal of the breast tissue, leaving the overlying skin, nipple
and areola in place) and total mastectomy where as much breast
tissue as possible is removed by excising an ellipse of skin
(including the nipple and areola and underlying breast tissue
down to the fascial plane overlying the chest wall). In subcutane-
ous mastectomy the nipple areola complex is partially preserved
and this tissue remains at risk for malignant transformation and
the spared nipple areola complex is insensate, because the under-
lying breast tissue bearing the nerve branches undergoes scarring
and retraction. More recently skin sparing techniques with
immediate breast reconstruction have been further refined in the
management of breast cancer and have been adopted for prophy-
lactic mastectomy [59]. Breast tissue and the areolar complex are
removed in skin sparing mastectomy but the inframammary fold
and the breast skin are preserved. At the present time, many
experts recommend total mastectomy because this method
removes as much tissue at risk as possible.
Psychosocial consequences. Few studies with a small number of
patients have specifically addressed the psychosocial sequelae
of prophylactic mastectomy in high-risk women. Twenty-six
Swedish women were studied prospectively to determine the
psychiatric and psychosocial outcomes of subcutaneous mastect-
omy with immediate reconstruction [60]. Only one of these
women had surgery for familial breast cancer. At 8 weeks and
1 year after surgery, the majority of women were satisfied with
their surgery, but a considerable proportion reported feelings
of depression and some impact on their sexuality. In a small
qualitative study of 10 women who underwent cutaneous prophy-
lactic mastectomy with immediate reconstruction no adverse
psychological sequelae were described [61].
Prophylactic oophorectomy
In recent times laparoscopic-assisted surgery has been used to
perform prophylactic oophorectomy on women with family
histories of ovarian cancer. Prophylactic oophorectomy is most
commonly prescribed as a strategy to reduce ovarian cancer.
Surgical complications specifically attributable to prophylactic
oophorectomy are not well described. Possible non-fatal compli-
cations of prophylactic oophorectomy include infection, bleeding
and urinary tract and bowel injury [62].
Unfortunately, the occurrence of peritoneal cancer, or as it is
sometimes called ‘papillary serous carcinoma of the periton-
eum’, after prophylactic oophorectomy has been well described
[63]. There are two hypotheses about the origin of peritoneal
cancer after oophorectomy: (i) the tumor develops from an occult
primary ovarian focus with subsequent spread through the periton-
eum, or (ii) it is a de novo disease originating from the peritoneal
mesothelium, which has a common origin with the Mullerian
duct epithelium from which epithelial cancer develops. Recent
molecular evidence suggests that peritoneal cancer may be multi-
focal with a polyclonal origin, supporting the second hypothesis
[64]. Two retrospective studies by Struewing et al. [65] and Piver
et al. [63] documented 44 and 324 patients, respectively, who
underwent prophylactic oophorectomy because of a family history
of ovarian cancer. These studies describe an incidence of two and
six peritoneal cancers, respectively, between 1 and 27 years of
age after prophylactic oophorectomy.
Efficacy. The effectiveness of prophylactic oophorectomy in
known BRCA1 and BRCA2 carriers has also been studied in the
two decision models of Grann et al. [50] and Schrag et al. [49].
They assumed that prophylactic oophorectomy has an efficacy of
50% in carriers. The estimated penetrance of ovarian cancer in
carriers in the high-risk group was higher in the Grann model but
both studies found that prophylactic oophorectomy in a 30-year-
old carrier resulted in 1.7 to 2.8 additional years of survival. In the
Grann model, quality-of-life analysis resulted in 0.5 additional
life years. In both models the benefits were lower with increasing
age at prophylactic oophorectomy and with lower ovarian cancer
penetrance estimates. The optimal timing for prophylactic
oophorectomy has not yet been determined. This is important,
because loss of fertility, potential risk of cardiovascular disease,
osteoporosis and premature menopausal symptoms must be
balanced against an age-adjusted risk of ovarian cancer. In
hereditary ovarian cancer [66, 67] the mean age of onset has been
reported to be 48–51 years in several series. These figures have
led some to suggest that prophylactic oophorectomy could be
deferred to a later age to minimize the negative side-effects of
premature loss of ovarian function. However, because ovarian
cancer has been reported in BRCA1 mutation carriers in their
thirties, an NIH Consensus Development Panel on ovarian cancer
[32] recommended that prophylactic oophorectomy should be
performed after childbearing has been completed or after 35 years
of age.
New data from two large studies recently published in the New
England Journal of Medicine show that the benefit from prophy-
lactic oophorectomy is substantial for both breast and ovarian
cancer risk. A prospective follow-up study by Kauf et al. [68]
of 170 women with BRCA1 or BRCA2 mutations choosing to
undergo either surveillance or salpingo-oophorectomy demon-
strated that after a mean follow-up of 24.2 months, bilateral
oophorectomy resulted in an ovarian cancer risk reduction of
85% and a breast cancer risk reduction of 68%. An accompany-
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ing article reporting the results of a multicenter retrospective
analysis of 551 women carrying mutations in either BRCA1 or
BRCA2 from Rebbeck et al. [69] showed a risk reduction for
coelomic epithelial cancer of 96% and for breast cancer of 53%
after bilateral prophylactic oophorectomy. These results confirm
previous reports [65, 70] that the risk of breast cancer is sub-
stantially reduced after prophylactic oophorectomy. Moreover,
the study by Rebbeck et al. [69] supports the practice of
performing prophylactic oophorectomy in BRCA1 or BRCA2
carriers as soon as possible after childbearing is completed
because of a mean age at diagnosis of ovarian cancer of 50.8
(range 30–73 years). In addition, the use of hormonal replace-
ment therapy did not abolish the beneficial effect of oophor-
ectomy on breast cancer risk. Although opinions on the use of
hormonal replacement therapy after prophylactic oophorectomy
are divided, this finding together with quality of life issues may
facilitate the decision to use estrogens in premenopausal women,
making prophylactic oophorectomy more acceptable for these
women. In 2001, two studies were published concerning
fallopian tube carcinomas [71, 72], which suggested that the
procedure of choice in BRCA mutation carriers is bilateral
salpingoophorectomy possibly with hysterectomy.
In summary, because effective risk reduction measures such
as salpingo-oophorectomy are now available for healthy women
with BRCA1 or BRCA2 mutations, many experts feel that
attitudes towards genetic testing for hereditary breast and ovarian
cancer syndromes should be changed and individuals at risk
encouraged to undergo genetic testing.
Endocrine changes. Apart from the loss of fertility with the onset
of postmenopausal symptoms, oophorectomy causes other
physiological changes in premenopausal women. It is associated
with adverse changes in lipid profile [73] and confers an approxi-
mately two-fold increase in coronary artery disease risk [74].
Oophorectomized women have an increased incidence of
osteoporosis [75]. These symptoms may be reduced by the use of
hormonal replacement therapy. However, the use of exogenous
estrogen is of particular concern in women with an increased
breast cancer risk due to a hereditary susceptibility. Data on
adverse effects concerning the breast cancer risk in young BRCA
mutation carriers is pending.
Psychosocial considerations. Several authors have investigated
the effect of oophorectomy on sexuality and mood. Nathorst-
Boos et al. [76] examined the effect of hysterectomy with and
without bilateral oophorectomy on sexual function and psycho-
logical status and androgen levels in 101 Swedish women. Only
half of the women were given hormonal replacement therapy.
Oophorectomized women reported lower libido and sexual dis-
satisfaction regardless of the use of hormonal replacement
therapy (HRT) and levels of circulating androgens. General
psychological well-being was lowest in the oophorectomy
groups, but the use of HRT negated this difference. In a retro-
spective study, Dennerstein et al. [77] found high levels of sexual
dysfunction in a sample of 89 women interviewed up to 5 years
after hysterectomy and prophylactic ovariectomy. In contrast,
Everson et al. [78] were unable to demonstrate an adverse
psychological effect of menopause in a small sample of women
with bilateral oophorectomies who were studied prospectively in
the healthy women study.
Lifestyle modifications
A number of studies have identified potentially modifiable non-
genetic risk factors for breast cancer, such as reproductive
factors, hormonal replacement therapy, hormonal contraception,
increased dietary fat intake [79, 80], body weight, physical
activity [81], alcohol intake [82] and decreased antioxidant
vitamin intake.
Body weight. The relationship between body mass index and
breast cancer risk changes with age during a woman’s lifetime.
Whereas a higher body mass index is associated with protection
against premenopausal breast cancer [83, 84], an increased risk of
breast cancer with higher body mass index was observed among
postmenopausal women [85].
Dietary factors. The potential role of dietary factors in breast
cancer has been difficult to establish. Many case–control studies
have examined the association, and in contrast to cohort studies,
have tended to favor at least a weak association  between dietary
fat and breast cancer [86]. A recent case–control study conducted
in Indonesia, a country with a low overall fat intake, observed a
strong dose–response trend between dietary fat intake and like-
lihood of breast cancer, especially during premarital years [87].
Concerning the intake of vitamins, in a large prospective cohort
study a protective association for vitamin C intake from foods
for premenopausal breast cancer among women with a family
history was observed [88].
Phytoestrogens are plant-derived compounds with estrogen
agonist and antagonist effects that have been linked to a low risk
of breast cancer in some observational reports [89]. Studies to
determine whether phytoestrogens promote the risk of breast
cancer or not are underway.
Physical activity. A large prospective cohort study indicated that
leisure time physical activity during adulthood was associated
with decreased breast cancer risk [90]. In a study that focused on
postmenopausal breast cancer, cumulative exercise patterns from
menarche onwards showed an impressive lowering of risk.
Interestingly, the protective influence of exercise was most
pronounced among women who had avoided substantial weight
gain during adulthood [91]. Despite evidence to support a link
between physical activity and breast cancer, a definitive associ-
ation has not yet been established.
No data are available so far on the effect of body weight, diet
and physical activity for carriers of BRCA mutations.
Use of oral contraceptives. A small study reported that long-term
oral contraceptive use before a full-term pregnancy may increase
breast cancer risk in BRCA1 and BRCA2 carriers [92]. However,
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a case–control study demonstrated that the use of oral contra-
ceptives by BRCA1 mutation carriers decreases the risk of
ovarian cancer by 50% [93]. A recently published historical
cohort study [94] of 426 families of breast cancer probands
suggests that women who have ever used formulations of oral
contraceptives during or prior to 1975 with a first-degree relative
with breast cancer may be at particularly high risk of breast
cancer. BRCA1 and BRCA2 mutation screening among high-risk
families in this study is currently being undertaken to determine
the association of breast cancer with oral contraceptive use in
these families. These findings suggest that the impact of oral
contraceptive use on breast and ovarian cancer risk in BRCA1 and
BRCA2 mutation carriers needs to be examined more closely
before any firm recommendations on their use in women with
these mutations can be made.
Use of HRT. Observational studies have suggested that post-
menopausal HRT halves the risk of coronary heart disease and
osteoporosis but increases the risk of breast cancer by 30–40%
[95]. However, the reduction in the risk of coronary heart disease
could not be demonstrated in a recently published placebo-
controlled randomized trial with HRT for secondary prevention
of heart disease in postmenopausal women [96], nor was the
progression of established coronary atherosclerosis affected by
estrogen (plus or minus medroxyprogesterone acetate) [97].
Moreover, the cumulative effect of HRT on breast cancer risk
has raised concerns about the practice of prescribing HRT for
10 years or longer. In a meta-analysis of 51 case–control and
cohort studies of 52705 women with breast cancer and 198411
women without breast cancer, short-term use of HRT (<5 years)
was not associated with breast cancer risk [98], but a 35%
increase in breast cancer risk was seen in women using estrogen
replacement therapy for 5 years or longer. Because the risk of
osteoporosis may also be lowered through the use of other drugs,
most experts feel that the use of HRT in postmenopausal women
needs to be re-examined.
The balance between risks and benefits may shift significantly
for women with a substantially increased risk of breast cancer.
Although the relative risk associated with HRT does not appear
to be higher in women with a family history of breast cancer, the
absolute benefit of HRT measured as the net increase in life
expectancy falls according to decision analysis as the risk of
breast cancer increases [99]. In one of the models, HRT no longer
increased life expectancy in women with a lifetime breast cancer
risk above 30%. Although the number of postmenopausal women
with such a high breast cancer risk is small, assessment of breast
cancer risk provides valuable information for making decisions
about HRT. With respect to ovarian cancer risk, a new 14-year
study of more than 211000 postmenopausal women showed that
women who take estrogens for ≥10 years [100] doubled their risk
of dying of ovarian cancer, compared with those who did not take
the hormone.
Levels of evidence
A five-point rating system has been used to identify evidence for
key recommendations. Because, as in many other areas of medi-
cine, clinicians in cancer genetics have to make management
decisions in the absence of sound evidence, recommendations
based on clinical experience of respected authorities or reports of
expert committees have been included. At the same time, these
expert opinion-based recommendations represent areas in need
of high-quality research in the field (Table 1).
Recommendations for individuals at, or slightly above, average
risk for breast cancer. Risk category: lifetime risk of 12–15%.
Family history:
• no confirmed family history of breast cancer;
• one first-degree relative diagnosed with breast cancer at ≥50
years of age;
• one second-degree relative diagnosed with breast cancer at
any age;
• two first- or second-degree relatives diagnosed with breast
cancer at ≥50 years of age.
Recommended model for risk calculation: Gail.
Management options for individuals at, or slightly above, aver-
age risk for breast cancer (Table 2).
Table 1. Level of evidence ratings
Level of evidence
I Evidence obtained from a systematic review of all relevant randomized controlled trials
II Evidence obtained from at least one randomized controlled trial
III-1 Evidence obtained from well-designed pseudorandomized controlled trials (alternate allocation or some other method)
III-2 Evidence obtained from comparative studies with concurrent controls and allocation not randomized (cohort studies), 
case–control studies or interrupted time-series with a control group
III-3 Evidence obtained from comparative studies with historical controls, two or more single-arm studies or interrupted 
time-series without a parallel control group
IV Evidence obtained from case series, either post-test or pre- and post-test
V Expert opinion (clinical experience of respected authorities or reports of expert committees), no published evidence
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Recommendations for individuals at moderately increased risk
for breast cancer. Risk category: lifetime risk of 15–29%.
Family history:
• One or two first-degree relatives diagnosed with breast cancer
at <50 years of age (without the additional features of the
potentially high-risk group described below).
• Two first- or second-degree relatives on the same side of the
family diagnosed with breast or ovarian cancer at <50 years
of age (without the additional features of the potentially high-
risk group described below).
Recommended models for risk calculation: Claus and Gail.
Management options for individuals at moderately increased risk
for breast cancer (Table 3).
Recommendations for individuals at highly increased risk for
breast cancer due to a known BRCA mutation or with a family
history suggestive of hereditary breast or ovarian cancer but no
detectable mutation or no genetic testing. Risk category: lifetime
risk of 30–80%.
Personal characteristics associated with an increased likeli-
hood of BRCA1 or BRCA2 mutations are as follows:
• breast cancer diagnosed at an early age;
• bilateral breast cancer;
• a history of both breast and ovarian cancer.
Family history characteristics associated with an increased likeli-
hood of BRCA1 or BRCA2 mutations [8] are as follows:
• two or more family members <50 years of age with breast
cancer;
Table 2. Management options: slightly above average risk for breast cancer
aCounseling regarding possible health benefits of a low-fat, high-fiber diet with an intake of at least five servings of 
fruit and vegetables daily, regular exercise and avoidance of carcinogens, such as cigarette smoking, is encouraged. 
Although dietary and exercise measures are unproven means to reduce breast cancer risk, they have a broad range 
of other health benefits. Moreover, lifestyle modifications give individuals with an increased breast cancer risk the 
opportunity to take active steps to promote their health. However, sufficient explanation should be given 
concerning the uncertainty of benefits in cancer risk reduction to permit latitude for individual choice.
Level of 
evidence
Monthly breast self-examination V
Advise to visit general primary care physician promptly if any breast changes are noticed V
Clinical breast examination every year II
Mammography every second year after 50 years of age I
Regular exercise III-2a
At least five servings of fruit or vegetables daily and a fat intake ≤60 g daily Va
Avoidance of smoking Va
Not being overweight Va
Table 3. Management options: moderately increased risk for breast cancer
aCounseling regarding possible health benefits of a low-fat, high-fiber diet with an intake of at least five servings of fruit and vegetables daily, regular 
exercise and avoidance of carcinogens, such as cigarette smoking, is encouraged. Although dietary and exercise measures are unproven means to reduce 
breast cancer risk, they have a broad range of other health benefits. Moreover, lifestyle modifications give individuals with an increased breast cancer risk the 
opportunity to take active steps to promote their health. However, sufficient explanation should be given concerning the uncertainty of benefits in cancer risk 
reduction to permit latitude for individual choice.
Level of 
evidence
Monthly breast self-examination V
Advise to visit general primary care physician promptly f any breast changes are noticed V
Clinical breast examination every 6 months II
Mammography every year from the age of 40 years; additional surveillance, such as mammograms at a younger age or more frequent 
mammograms, should be considered on an individual basis, as evidence for the optimal strategy in this group does not currently exist
I
Participation in clinical trials for the chemoprevention of breast cancer should be discussed
Regular exercise III-2a
At least five servings of fruit or vegetables daily and a fat intake ≤60 g daily Va
Avoidance of smoking Va
Not being overweight Va
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• both breast and ovarian cancer in the family;
• male breast cancer;
• one or more family members <50 years of age with breast
cancer and Ashkenazi Jewish background.
Recommended model for calculation of BRCA mutation proba-
bility: BRCAPro and Myriad.
Recommended model for risk calculation without genetic testing
or without detectable BRCA mutation: Claus.
Management options for individuals at highly increased risk for
breast cancer due to a known BRCA mutation or with a family
history suggestive of hereditary breast and/or ovarian cancer
with no detectable mutation or no genetic testing (Table 4).
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